Value
7.6/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 6.7 |
| Fwd P/E | 5.6 |
| PEG | 10.0 |
| Analyst target | 9.0 |
- ▸Forward P/E: 22.8x
- ▸PEG: 0.06
- ▸Attractively valued
TARS · Why this verdict
Why Tarsus Pharmaceuticals (TARS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score6.0/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue is growing at 107% year-over-year, placing Tarsus among the top growth stories in biotechnology and reflecting rapid uptake of XDEMVY in the treatment of Demodex blepharitis, a validated commercial market. Growth breakdown | Revenue growth remains above 50% in at least 3 of the next 4 reported quarters, confirming that XDEMVY penetration is continuing rather than plateauing. | →Stable |
| CounterTriple-digit growth from a single newly launched drug typically decelerates sharply in the second and third years as initial prescription waves saturate the early-adopter physician base. | ||
A Rule of 40 score of 103 combines growth and profitability at a level typically achieved only by the best-performing software companies; for a commercial-stage biotech, it indicates that XDEMVY's commercial model is unusually capital-efficient. Quality breakdown | The Rule of 40 score remains above 60 over the next four reported periods as growth moderates but gross margins compensate, confirming the business model quality. | →Stable |
| CounterA Rule of 40 score of 103 driven almost entirely by growth rate is unstable; as growth decelerates, the score will fall sharply unless operating profitability improves rapidly to compensate. | ||
All commercial revenue derives from a single product, XDEMVY, sourced through a contract manufacturer in Europe, creating a dual concentration risk where any manufacturing disruption or competitive entry could materially and rapidly reduce revenue. Bear case | XDEMVY maintains at least 70% market share in the Demodex blepharitis treatment category over the next 12 months with no new competitive drug approval in the United States. | →Stable |
| CounterFirst-mover advantages in ophthalmology are strong, with physicians highly reluctant to switch established patients to new therapies; XDEMVY's head start provides durable commercial protection that the concentration risk understates. | ||
A put-to-call ratio of 22.55 is extremely elevated and reflects intense institutional hedging or directional bearish bets, suggesting sophisticated market participants see material downside risk that the bullish growth narrative does not capture. Risk breakdown | The put-to-call ratio falls below 10 within 6 months as revenue beats reduce uncertainty and the extreme hedging position unwinds. | →Stable |
| CounterExtremely elevated put-to-call ratios in small biotech names are often driven by a small number of institutional positions and can reverse violently on positive news; the signal is less reliable for small-cap names than for large-cap stocks. | ||
Revenue is growing at 107% year-over-year, placing Tarsus among the top growth stories in biotechnology and reflecting rapid uptake of XDEMVY in the treatment of Demodex blepharitis, a validated commercial market.
→StableGrowth breakdown
- Expectation
- Revenue growth remains above 50% in at least 3 of the next 4 reported quarters, confirming that XDEMVY penetration is continuing rather than plateauing.
CounterTriple-digit growth from a single newly launched drug typically decelerates sharply in the second and third years as initial prescription waves saturate the early-adopter physician base.
A Rule of 40 score of 103 combines growth and profitability at a level typically achieved only by the best-performing software companies; for a commercial-stage biotech, it indicates that XDEMVY's commercial model is unusually capital-efficient.
→StableQuality breakdown
- Expectation
- The Rule of 40 score remains above 60 over the next four reported periods as growth moderates but gross margins compensate, confirming the business model quality.
CounterA Rule of 40 score of 103 driven almost entirely by growth rate is unstable; as growth decelerates, the score will fall sharply unless operating profitability improves rapidly to compensate.
All commercial revenue derives from a single product, XDEMVY, sourced through a contract manufacturer in Europe, creating a dual concentration risk where any manufacturing disruption or competitive entry could materially and rapidly reduce revenue.
→StableBear case
- Expectation
- XDEMVY maintains at least 70% market share in the Demodex blepharitis treatment category over the next 12 months with no new competitive drug approval in the United States.
CounterFirst-mover advantages in ophthalmology are strong, with physicians highly reluctant to switch established patients to new therapies; XDEMVY's head start provides durable commercial protection that the concentration risk understates.
A put-to-call ratio of 22.55 is extremely elevated and reflects intense institutional hedging or directional bearish bets, suggesting sophisticated market participants see material downside risk that the bullish growth narrative does not capture.
→StableRisk breakdown
- Expectation
- The put-to-call ratio falls below 10 within 6 months as revenue beats reduce uncertainty and the extreme hedging position unwinds.
CounterExtremely elevated put-to-call ratios in small biotech names are often driven by a small number of institutional positions and can reverse violently on positive news; the signal is less reliable for small-cap names than for large-cap stocks.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Tarsus Pharmaceuticals is growing revenue at 107% annually driven by its XDEMVY eye treatment, operates at an elite Rule of 40 score of 103, and analysts see 52% upside from $61.85, but extreme product concentration in one drug and an elevated put-to-call ratio of 22.55 signal the market is pricing in meaningful execution risk.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
4.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 9.3 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -4% of revenue
- ▸Rule of 40: 103 (elite)
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 107% YoY
Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 9.1 |
| OBV | 1.0 |
| MA position | 7.2 |
| Volume | 10.0 |
| vol acceleration | 8.0 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA but MA still rising (+1.9%/30d) — pullback in uptrend, not confirmed weakness
- ▸Volume surge (2.0x avg) on up move
Sentiment
5.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 1.2 |
| Analyst rating | 5.0 |
| Price target | 9.3 |
- ▸LLM news sentiment: -0.75 (n=2)
- ▸Analyst upside: 44%
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $2,269,420 (0.081% of mkt cap)
Peer rank
5.3/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 7.2 |
| quality rank | 5.6 |
| growth rank | 8.5 |
- ▸Industry growth leader
Technical
3.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.4 |
| support resistance | 3.1 |
| 52w position | 5.4 |
Risk (lower is worse)
4.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 4.0 |
| days to cover | 2.3 |
| volatility | 0.0 |
| put call | 6.7 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 10.0 |
| debt equity | 9.0 |
- ▸High IV: 103%
- ▸Concentration risks: 2 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 6.0 |
- ▸Earnings concerns: 2B/2M
How the verdict was assembled
Engine trigger
Mixed signals. Hold existing position. | News modifier -1 (HOLD_IF_HOLDING → SELL_IF_HOLDING).
Engine technical detail
verdict_path:
L4:PATH_F_HOLD_DEFAULT|L3:NEWS_MOD=-1Passed (7)
- MOMENTUM:6.6>=5.5
- ASYMMETRY:1.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:34d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- NEWS:LEGAL
Warning (0)
none
Reward-to-Risk
1.84
Upside
+25.1%
Downside
13.6%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The default F-path HOLD fired without any positive-conviction gate triggering — no momentum acceleration, no quality+value crossover, no setup recognition. Highest-clear gate: MOMENTUM:6.6>=5.5. Top dim: Growth at 10.0; weakest: Technical at 3.3. The engine's read is one of pattern absence — no directional conviction in either direction at current asymmetry.
The strongest dimensions are Growth at 10.0, Value at 7.6, and Momentum at 6.6; the weakest are Technical at 3.3, Insider at 3.8, and Catalyst at 3.9. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 1.84 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Revenue Growth 107 Percent
Trip ifYear-over-year revenue growth falls below 30% in at least 2 of the next 4 reported quarters, indicating commercial growth has decelerated significantly from the current 107% pace.
- P2Elite Rule Of 40 Score
Trip ifRule of 40 score falls below 40 in any reported period, indicating the business model quality has deteriorated to average or below-average levels.
- P3Xdemvy Single Product Concentration
Trip ifA competing drug receives FDA approval for Demodex blepharitis, or XDEMVY market share falls below 60% based on prescription data disclosed in any quarterly filing.
- P4Elevated Put Call Options Skepticism
Trip ifPut-to-call ratio remains above 15 for more than 90 consecutive days, indicating the extreme bearish positioning is structural rather than a transient hedge.